Adenovirus has been increasingly recognized as an important cause of morbidity and mortality after hematopoietic stem cell transplantation (HSCT) [1] [2] [3] [4] . Progression of adenovirus infection to disseminated adenovirus disease has been especially documented in pediatric HSCT recipients and in T cell-depleted HSCT recipients [1, [5] [6] [7] . Recent data obtained in these con-texts suggest that monitoring of blood samples for adenovirus DNA is a sensitive tool for the recognition of patients at risk for a potentially fatal infection [7] [8] [9] . Because the prevalence and disease association of different adenovirus species varies among transplant centers [10] [11] [12] [13] , any screening methods used in this population of at-risk patients should permit sensitive detection of all adenoviral serotypes.
In the context of T cell-replete HSCT, adenovirus disease is uncommon, and its correlation with adenoviremia is unknown [3] . The purpose of our study was to determine whether plasma adenovirus DNA detection is useful in identifying adenovirus disease in the low-prevalence context of T cell-replete HSCT, using a multiplex PCR assay with the ability to detect all human adenovirus species. 
METHODS
Because of the low prevalence of disease in the context of T cell-replete HSCT, we chose a case-control study design. Patients who received an allogeneic graft at the Fred Hutchinson Cancer Research Center (Seattle, WA) from 1 May 1978 through 1 August 1996 and had a frozen plasma specimen available for retrospective testing were eligible for the study. Three clinical groups of patients were selected from the computerized database: (1) patients with tissue-proven adenovirus disease; (2) patients with adenovirus infection, defined as patients who had positive results of surveillance-based culture of specimens from urine, the throat, and stool; and (3) uninfected control patients, defined as patients who had surveillance culture results that were negative for adenovirus. The case patients with plasma samples were included for the analysis. We randomly selected the same number of patients for groups 2 and 3 as we had selected for group 1. Nonmatching criteria were defined, and only patients with plasma samples were included in the analysis. Clinical and virologic parameters were extracted from our computerized database. Each patient had previously signed an informed consent form that allowed storage and use of their blood samples and clinical information for future research. The study received institutional review board approval at the Fred Hutchinson Cancer Research Center.
Sample collection and laboratory evaluation. From the beginning of the study period through 31 July 1994, prospective screening for adenovirus in stool, urine, and throat specimens was performed weekly for all inpatients and every 2 weeks for outpatients from the day of transplantation until day 100 or death, whichever occurred first. Samples from other sites were cultured as clinically indicated. Before August 1988, adenovirus screening was performed by conventional culture. Since August 1988, other adenovirus identification techniques have included shell vial cultures, direct fluorescent antibody testing, and EIA of stool samples. Tissue samples obtained from biopsy of the liver, gut, or lung are screened for adenovirus by routine histologic examination, immunocytochemical examination, or culture. When an autopsy is performed, specimens from the liver, spleen, a kidney, and both lungs are examined by viral culture and histologic examination. Bronchoalveolar lavage and ocular swab specimens are routinely examined by conventional viral culture, shell vial culture, and/or direct fluorescent antibody testing.
Plasma samples, stored at Ϫ20ЊC for future analysis, were collected weekly, starting from the day of transplantation until discharge from the cancer center or death, whichever occurred first. Plasma samples were retrospectively screened for all human pathogenic adenoviruses in a blinded manner using 2 multiplexed quantitative real-time PCR assays, as described elsewhere [14] . One assay detected subgroups A and F (AdV-AF PCR), and 1 detected subgroups B, C, D, and E (AdV-BCE PCR). The primers that were used for the first assay were HexonA-1 (CCGGKCTGGTGCAATTCG), HexonA-2 (CGA TCCACGGGCACAAA), HexonF-1 (TGTTYGAAGTTTTCGA-CGTYGT), and HexonF-2 (SAGGTAGACGGCCTCGATGA); the probes that were used were HexonA-P (CCACGGACACC-TACTTCACCCTGGG) and HexonF-P (CGCATCCACCA-GCCSCACC). For the second assay, the primers were HexonB-1 (TGGACATGACYTTTGAGGTGGAT), HexonB-2 (CGTCGAARACTTCGAARAGAAGA), HexonE-1 (TTAACC-ACCACCGCAATGC), HexonE-2 (TGGATGTGGAATGGCA-CGTA), PentonC-1 (TCGACACCACCCGTGTGTAC), and PentonC-2 (TGCTGTGGTCGTTCTGGTAGTT); the probes sequences were HexonB-P (CCATGGATGAGCCCACCCTGC-TTT), HexonE-P (TACCGCTCCATGCTCCTGGGCA), and PentonC-P (TGGACAACAAGTCAACGGATGTGGCA). DNA was extracted from 200 mL of eluted DNA and was eluted into 100 mL of buffer using QiaAmp96 DNA blood kit (Qiagen). Ten microliters of eluted DNA was then used for each PCR reaction. The sensitivity of the PCR assays permitted reliable detection of 10 copies per reaction or 500 copies/mL of plasma.
Definitions. Adenovirus-proven disease (group 1) was defined as clinical manifestation and organ dysfunction that were compatible with adenovirus infection, in the presence of adenovirus in biopsy, autopsy, bronchoalveolar lavage, or eye swab specimens. [3] . Patients who had adenovirus isolated in tissue specimens obtained from 1 organ or 11 organ were considered to have localized and disseminated disease, respectively. Adenovirus infection (group 2) was defined as the identification of adenovirus in surveillance-based culture specimens obtained from urine, the throat, or stool. The clinical charts of patients in group 2 who had plasma specimens that were positive for adenovirus were retrospectively reviewed. Patients in group 2 who had symptoms compatible with adenovirus disease associated with adenoviremia were defined as having possible adenovirus disease (group 2A). Uninfected control patients (group 3) were defined as patients who had surveillance-based culture of specimens routinely performed, with the cultures yielding negative results.
STATISTICAL ANALYSIS
Fisher's exact test was used to compare the frequencies of viremia between each group. The Kruskall-Wallis nonparametric method was used to compare the plasma viral loads measured in each group. For the subset of patients with proven adenovirus disease, only samples obtained before the definitive diagnosis of disease were considered for analysis. Sensitivity and specificity of adenoviremia as an indicator for adenovirus disease were assessed in 2 ways. First, we defined patients with adenovirus disease as patients with adenovirus-proven disease (group 1), and then we expanded the definition to include patients with both adenovirus-proven disease (group 1) and possible disease (group 2A), which included patients with adenovirus infection who had plasma specimens that tested positive for adenovirus and who had symptoms compatible with adenovirus disease. P values were 2-sided. Statistical significance was determined at . Analysis was performed using Stata software, ver-P p .05 sion 9.0 (Stata).
RESULTS

Patients
Sixty-two HSCT recipients were identified from the Fred Hutchinson Cancer Research Center computerized database and had plasma specimens tested for adenovirus DNA; 24 of these patients had proven adenovirus disease (group 1), 19 had adenovirus infection (group 2), and 19 were uninfected control patients (group 3).
Of the 24 patients with proven adenovirus disease who were selected, 14 (58%) presented with disseminated disease a median of 84 days (range, 29-633 days) after HSCT, and 10 (42%) presented with localized disease a median of 82 days (range, 46-780) after HSCT. The diagnosis was made at autopsy for 12 (85%) of 14 patients with disseminated disease and 2 (20%) of 10 patients with localized disease. Among the patients who died with autopsy-proven adenovirus infection (12 with disseminated disease and 2 with localized disease), adenovirus was the only organism isolated in 8 (66.6%) of 12 patients with disseminated disease and in 1 (50%) of 2 patients with localized disease. For these patients, adenovirus disease was found to be the only cause of death.
The mean numbers (‫ע‬SD) of plasma samples that were available for adenovirus testing were samples, 10.8 ‫ע‬ 4.2 , and from groups 1, 2, and 3, respectively. 8.1 ‫ע‬ 3.8 13.3 ‫ע‬ 3.2 The demographic and clinical data of each group are shown in table 1.
Adenovirus Viremia
Adenovirus DNA was detected in 91 of the 668 plasma samples collected. Plasma samples were obtained from 21 patients with proven adenovirus disease (group 1; 75 samples were positive for adenovirus, 66 of which were obtained before diagnosis of disease). Fourteen plasma samples that were positive for adenovirus were obtained from 4 patients who shed adenovirus (group 2) a median of 35 days (range, 14-43 days) after HSCT. One of the 19 uninfected control patients (group 3) presented with transient adenoviremia, which was detected on day 4 after HSCT. Of the 26 patients with adenoviremia, 10 shed adenovirus in urine, feces, or throat specimens for a median duration of 20 days (range, 0-40 days) prior to the first detection of viral DNA in plasma specimens. For 7 patients, the virus was isolated in urine, feces, or throat specimens a median of 7 days (range, 1-21 days) after the first detection of viral DNA in plasma specimens. Nine patients with adenoviremia did not shed adnovirus. Adenovirus subgroup BCDE was found in all patients who had adenoviremia. Subgroup AF was only found in 1 patient in group 2.
Proven adenovirus disease (group 1). Of the 24 patients with proven adenovirus disease, 21 (87.5%; 7 children and 14 adults) developed adenoviremia before receiving the definitive diagnosis of disease. All but one of the patients in group 1 had a sustained and increasing plasma viral load. The median time between the first detection of adenovirus in blood specimens and the diagnosis of disease was 15 days (range, 2-48 days). One patient had adenovirus DNA detected once (DNA level, copies/mL), after which no further samples were Median maximum plasma viral load, by group of adenovirus manifestation. The median maximum viral load in patients with adenovirusproven disease (group 1) was significantly higher than that in patients with possible disease or asymptomatic infection (group 2; ) and that P ! .001 in uninfected control patients (group 3;
). Among patients who received diagnoses based on autopsy findings, the viral loads were similar P ! .001 whether the patients presented with disseminated or localized disease ( ). The boxplot displays the median maximal, the interquartile range, P p .10 and the fifth and 95th percentile of maximal viral load. The dot in group 3 represents the maximum viral load of the single positive sample, and the dot in group 1 is an outlier.
available. The median initial DNA level was copies/ 4 8.1 ϫ 10 mL (range, to copies/mL), with a median 3 3 1.32 ϫ 10 6.12 ϫ 10 maximum DNA level of copies/mL (range, 7 1.64 ϫ 10 to copies/mL). Twenty-one patients died 4 9 3.29 ϫ 10 1.05 ϫ 10 of ongoing adenovirus-associated disease, 20 of whom had viral DNA detected in plasma specimens at a median of 19.5 days (range, 8-48 days) before death.
There were 3 patients (12.5%) who had negative results of PCR of plasma samples. The first patient died with disseminated cytomegalovirus disease and also had adenovirus isolated from the kidney autopsy specimen. This patient developed renal failure a few days before death, and no plasma samples were available for analysis within 21 days before death. The second patient developed interstitial pneumonia and had adenovirus isolated by culture from a lung tissue biopsy specimen. This patient completely recovered within a few days with empirical antibacterial treatment and no dose modification of steroids given for treatment of graft-versus-host disease. The third patient presented with severe hemorrhagic cystitis and renal function impairment; adenovirus was isolated from kidney and bladder biopsy specimens. This patient had plasma samples obtained until 10 days before the initial symptoms of cystitis and until 20 days before the diagnosis was determined by culture of a tissue specimen, after which no further samples were available. We cannot exclude that this patient was colonized with a rare strain that our assay was not able to detect.
Adenovirus infection (group 2). Four (21%) of 19 patients who had adenovirus isolated by surveillance-based culture from a mucosal site had adenovirus viremia detected by PCR. The maximum DNA level ranged from copies/mL to 7 2.8 ϫ 10 copies/mL. The minimum DNA level in all 4 patients 8 1.74 ϫ 10 was 110 3 copies/mL. The clinical charts of these patients were reviewed. All 4 died 9-41 days (median, 24 days) after the first detection of adenovirus in plasma specimens, and all presented with clinical symptoms that were compatible with adenovirusassociated disease. Two adult patients developed long-lasting severe hematuria associated with renal function impairment. Both patients had several cultures of urine samples that were positive for adenovirus, suggesting the presence of adenovirusassociated hemorrhagic cystitis ( figure 1A and D) . One pediatric patient had adenovirus detected in a bronchoalveolar lavage specimen obtained 15 days prior to transplantation; the patient recovered. A few days after transplantation, the patient developed fatal pulmonary failure, rapid renal function deterioration, and severe adenovirus-associated hemorrhagic cystitis (figure 1B). The fourth patient died of multiple organ failure in the context of disseminated cytomegalovirus and Candida disease. Postmortem kidney examination revealed viral inclusions suggestive of adenovirus; however, tissue cultures for detection of adenovirus could not be interpreted because of bacterial contamination ( figure 1C ). All 4 patients presented with a clinical course that was compatible with adenovirus disease and were categorized as having possible disease because of the absence of tissue-proven diagnosis (group 2A).
Uninfected control patients (group 3). One (5%) of 19 asymptomatic control patients had 1 plasma sample in which adenovirus DNA was detected. The DNA level was 40.3 copies/ mL. All subsequent plasma samples yielded negative results by PCR.
Frequency of adenoviremia and quantification of viral load. The frequency of adenovirus DNA detection in plasma specimens was significantly higher among patients with adenovirusproven disease (group 1; 87.5%) than it was among patients with symptomatic and asymptomatic adenovirus infection (group 2; 21.0%;
) and among uninfected control pa-P ! .001 tients (group 3; 5%; ). The frequency of DNAemia P ! .001 observed among groups 2 and 3 was not statistically different ( ) . P p .34
The median maximum plasma viral load observed in group 1 ( copies/mL; range, 0 to copies/mL) was 6 9 6.29 ϫ 10 1.05 ϫ 10 significantly higher than that in group 2 (0 copies/mL; range, 0 to copies/mL; ) and in group 3 (0 copies/ 8 1.74 ϫ 10 P ! .001 mL; range, 0 to copies/mL; ). The median 1 4.03 ϫ 10 P ! .001 maximum viral loads in groups 2 and 3 were not significantly different ( ). P p .12 Importantly, all but 1 patient with proven (group 1) or possible adenovirus disease (group 2A) had a sustained and increasing viral load after the first detection of adenovirus DNA in plasma specimens. All patients had results positive for adenovirus before disease was proven, and all had a minimum viral load of 10 3 copies/mL. To assess whether the viral load was different between patients with disseminated disease and patients with localized disease, we restricted the analysis to patients who had the diagnosis established at autopsy and who, therefore, had samples from the liver, lungs, and kidneys tested. The maximum DNA levels in 12 patients with disseminated disease (median viral load, copies/mL; range, to cop-
3.07 ϫ 10 1.32 ϫ 10 6.76 ϫ 10 ies/mL) appeared to be higher than those in 2 patients with localized disease (range, to copies/mL; 4 5 3.03 ϫ 10 9.65 ϫ 10 ) ( figure 2) ; however, the difference did not reach sta-P p .10 tistical significance ( ). P p .1 Among the patients with adenovirus-proven disease, viral load did not significantly differ on the basis of the organ involved ( figure 3 ). Interestingly, a high viral load was detected even in a patient with ocular disease.
Sensitivity and specificity. The sensitivity and specificity of PCR of plasma specimens to detect adenovirus disease are displayed in table 2. A sustained increase in viral load or a viral load 11000 copies/mL did not affect the sensitivity but improved the specificity of plasma PCR to diagnose proven (group 1) and possible adenovirus disease (group 2A).
DISCUSSION
Although adenovirus disease is relatively uncommon in T cellreplete HSCT recipients, this condition is associated with a high mortality rate. We used quantitative real-time PCR assays cov- ) and patients from group 2 who presented with sympn p 24 toms that were compatible with adenovirus disease (group 2A;
), for n p 4 whom no tissue culture was performed.
c Defined as у2 consecutive plasma samples testing positive for adenovirus DNA.
ering the entire spectrum of the known human adenovirus types to analyze plasma samples from HSCT recipients who had proven adenovirus disease. Results were compared with those for HSCT recipients who were shedding adenovirus from different sites and with those for uninfected HSCT recipients. Adenovirus DNA was detected in plasma specimens from most patients with adenovirus-proven disease (group 1) but was detected only infrequently in specimens from adenovirus shedders (group 2) and uninfected control patients (group 3). Patients with proven (group 1) or possible (group 2A) disease developed persistent and increasing plasma viral loads у1000 copies/mL several days before disease onset. In asymptomatic shedders and uninfected patients, no detection or only transient detection occurred when the plasma DNA level was very low. Indeed, only 1 uninfected control patient had a transient low plasma DNA level (40 copies/mL), and plasma samples from 15 asymptomatic adenovirus shedders consistently tested negative for virus. Three patients with proven adenovirus disease had negative plasma PCR results; however, 2 of these patients had samples available only until 3 weeks before disease onset, and the evaluation of viremia was incomplete. The third patient, identified by a positive result of culture of a lung biopsy specimen, probably only had a low level of pulmonary shedding, because the patient experienced complete recovery of pneumonitis quickly after the initiation of empirical antibacterial therapy and no modification of anti-graft-versus-host disease corticotherapy. Thus, increasing viral load or detection of a plasma viral load 11000 DNA copies/mL appear to be specific and sensitive indicators of adenovirus disease in non-T celldepleted HSCT recipients.
Importantly, plasma viral DNA was detectable at a median time of 20 days before death in patients who died with proven (group 1) or possible adenovirus disease (group 2A) and at a median of 8 days before a definitive diagnosis was determined on the basis of test results of a biopsy specimen in those who survived.
Overall, the performance characteristics of PCR of plasma specimens to detect adenovirus, which may serve as an alternative if invasive diagnosis is not feasible, appear to be a valuable marker to diagnose adenovirus disease and to justify the initiation of an appropriate therapy.
Although no antiviral drug has been formally approved for treatment of adenovirus infection, clinical observation and in vitro data have revealed that cidofovir has the strongest antiadenovirus activity, and a moderate antiviral effect was observed with ganciclovir; no antiviral inhibition was seen with acyclovir or ribavirin therapy [15] [16] [17] [18] [19] .
Because of the low prevalence of adenovirus disease in T cell-replete HSCT recipients, systematic screening for plasma viral DNA is probably not justified. However, the present data suggest that adenovirus screening of plasma specimens should be recommended as soon as a patient presents with symptoms that are compatible with adenovirus infection. Because adenovirus DNA was consistently detected before disease onset at levels of at least 1000 copies/mL in patients with proven or possible disease, a potential strategy might be to treat patients with a plasma DNA level 11000 copies/mL and to frequently retest any patients who have positive PCR results.
This study has strengths and limitations. The strengths are the large number of patients with adenovirus disease who were tested for viremia in the low-prevalence context of T cell-replete HSCT, the appreciable number of samples that were available for testing, and the systematic assessment of adenovirus disease at autopsy. One of the limitations is that the case-control design of the study prevents us from providing the predictive value of plasma PCR to detect adenovirus. Finally, because samples were essentially available during the first 3 months after transplantation, the study could not determine whether adenoviremia would have the same significance when it is detected late after transplantation.
This study has shown that plasma PCR to detect virus is a valuable tool to identify patients with adenovirus disease during the first 3 months after T cell-replete HSCT. An early treatment strategy based on the results of PCR assay of plasma samples is likely to reduce the mortality rate associated with adenovirus disease. In addition, identification of patients at risk for adenovirus disease by plasma PCR assay may allow doctors to avoid the use of invasive diagnostic procedures in critical situations.
